How Aging Hijacks Cell Signals in Blood Stem Cells — and How to Reverse It

Aging reshapes the blood and immune system. Blood stem cells lose self-renewal, production tilts toward myeloid cells, inflammation rises, and the risk of clonal expansion and hematologic malignancy grows. This narrative review in Aging Cell argues that extracellular vesicles (EVs), the membrane-enclosed nanoparticles cells use to swap proteins, lipids, and RNA, are active drivers of that decline rather than passive bystanders. The authors note that EVs collectively present more membrane surface than circulating leukocytes, so their surface molecules matter as much as their cargo.

The review first covers EV biology. Tetraspanins (CD9, CD63, CD81), ESCRT proteins, and SNAREs govern vesicle formation and release. Only about 20%-30% of internalized EVs deliver cargo into the recipient cytoplasm. Genotoxic, oxidative, and inflammatory stress activates p53 and NF-κB, which raises Rab27a/b and speeds vesicle release. The authors stress methodological problems. Ultracentrifugation, size exclusion, polymer precipitation, and affinity capture each carry distinct contaminants, and aging raises lipoproteins and protein aggregates that make isolation even harder. They follow MISEV guidelines, calling vesicles under 200 nm small EVs.

In healthy hematopoiesis, mouse HSCs take up labeled EVs from MS-5 stromal cells within 4 hours. TGF-β/SMAD signaling is a key axis. Blocking ALK5 produced SMAD2-depleted vesicles and impaired stem cell quiescence, and calpeptin-mediated EV inhibition in mice depleted SMAD2/pSMAD2 in marrow vesicles. Osteoblast EVs, carrying tRNA fragments such as 5'-ti-Pro-CGG-1, are preferentially taken up by granulocyte-macrophage progenitors. Boosting osteoblasts with intermittent PTH sped myeloid recovery after irradiation and improved survival against Candida albicans.

With age the picture changes. Senescent endothelial cells shed roughly 3-fold more small EVs enriched in miR-21-5p and miR-217, which lower sirtuin 1 and DNMT1 in healthy cells. EVs from aged mouse marrow (24-28 months) are enriched in the miR-183 cluster, and miR-183-5p suppresses Hmox1, impairing stromal proliferation and osteogenesis. Aged osteocytes lose vesicular tropomyosin-1, shifting marrow stromal cells toward fat via Pparg. Grancalcin rises 10-15 fold in aged rat neutrophils and macrophages, and recombinant grancalcin reduced osteoblasts and osteoclasts while increasing marrow fat in mice. EVs from aged mouse monocytes and macrophages (20-24 months), given to young mice, increased senescence, worsened insulin sensitivity, and accelerated bone loss.

The review also describes a reversible side. EVs from young iPSCs and MSCs carry antioxidant enzymes PRDX1 and PRDX2, reduce oxidative stress, and partially rejuvenate aged HSCs. Human data are mixed. Plasma EV concentration was lower in middle age than in younger adults in one study, but higher in people near 80 than in those aged 20-30 in others. EVs from older donors were internalized faster by monocytes and B cells in vitro, shifting their activation.

The authors emphasize important caveats. Human steady-state EV biology in marrow is largely unmapped, species and cohorts disagree, and isolation artifacts can distort findings. Standardized, validated protocols will be needed before EV signatures can serve as clinical biomarkers or EV-based rejuvenation therapies can be tested.